# A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis

> **NCT00527410** · PHASE1 · TERMINATED · sponsor: **Biogen** · enrollment: 9 (actual)

## Conditions studied

- Leptomeningeal Carcinomatosis

## Interventions

- **DRUG:** RTA 744

## Key facts

- **NCT ID:** NCT00527410
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10-31
- **Primary completion:** 2008-12-01
- **Final completion:** —
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00527410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00527410, "A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00527410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*